LCAT and hyperlipidemia: Jia et al. demonstrated that Tan IIA ameliorates hyperlipidemia in rat models by modulating hepatic lipid metabolism through regulation of key enzymes and receptors, including cytochrome P450 family 7 subfamily A polypeptide 1 (CYP7A1), LDLR, sterol regulatory element binding protein-2 (SREBP-2), and lecithin cholesterol acyltransferase (LCAT), additionally, Tan IIA influenced macrophage cholesterol efflux through regulation of ABCA1 and CD36 expression (Jia L. Q. et al., 2016).